|
US20060264360A1
(en)
|
2002-04-12 |
2006-11-23 |
Yale University Office Of Cooperstive Research |
Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4
|
|
US20040053307A1
(en)
|
2002-06-17 |
2004-03-18 |
Wyeth |
Inhibition of T cell activation by butyrophilin 4 and B7-L1
|
|
AU2004242846A1
(en)
*
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
|
|
EP1702622A1
(en)
|
2005-03-18 |
2006-09-20 |
CONARIS research institute AG |
Soluble BTNL2 protein useful to inhibit inflammatory disorders
|
|
DK1999154T3
(da)
*
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
WO2008154516A2
(en)
|
2007-06-11 |
2008-12-18 |
The Board Of Regents, The Universtity Ot Texas System |
Btnl2 fusion protein for t-cell activity modulation
|
|
GB0717101D0
(en)
|
2007-09-03 |
2007-10-10 |
Cambridge Entpr Ltd |
Tumour marker
|
|
EP3663318A1
(en)
*
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
WO2011127418A1
(en)
|
2010-04-09 |
2011-10-13 |
Amgen Inc. |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
|
WO2011133886A2
(en)
*
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
IN2014CN03887A
(cg-RX-API-DMAC7.html)
*
|
2011-10-27 |
2015-10-16 |
Genmab As |
|
|
US10131709B2
(en)
|
2011-12-28 |
2018-11-20 |
Immunoqure Ag |
Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
|
|
HUE037186T2
(hu)
|
2011-12-28 |
2018-08-28 |
Immunoqure Ag |
Eljárás humán antitestek izolálására
|
|
US20150166630A1
(en)
|
2012-07-19 |
2015-06-18 |
Amgen Inc. |
Btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
|
EP2941438A1
(en)
|
2013-01-01 |
2015-11-11 |
Kahr Medical Ltd. |
Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
|
|
GB201300049D0
(en)
|
2013-01-03 |
2013-02-20 |
Transimmune Ag |
Method for obtaining immuno-stimulatory dendritic cells
|
|
GB201300052D0
(en)
|
2013-01-03 |
2013-02-20 |
Transimmune Ag |
Method for obtaining immuno-suppressive dendritic cells
|
|
CN110724193B
(zh)
|
2013-07-03 |
2023-05-05 |
因美诺克股份公司 |
人单克隆抗il-32抗体、多核苷酸、载体、宿主细胞、制备方法、组合物及应用
|
|
WO2015001047A1
(en)
|
2013-07-03 |
2015-01-08 |
Immunoqure Ag |
Method of providing anti-human cytokine antibodies for pharmaceutical use
|
|
CA2917112C
(en)
|
2013-07-03 |
2022-07-05 |
Immunoqure Ag |
Human anti-ifn-alpha antibodies
|
|
US20160376364A1
(en)
|
2013-11-29 |
2016-12-29 |
Csl Limited |
Method of treating cancer
|
|
EP3087099A4
(en)
*
|
2013-12-23 |
2017-07-19 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
US10501540B2
(en)
|
2014-04-10 |
2019-12-10 |
Lava Therapeutics B.V. |
Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
|
|
GB201413665D0
(en)
|
2014-07-03 |
2014-09-17 |
Transimmune Ag And Yale University |
Method for obtaining globally activated monocytes
|
|
CN106999584A
(zh)
|
2014-11-25 |
2017-08-01 |
阿尔伯特爱因斯坦医学院公司 |
Btnl9和ermap作为用于免疫疗法的新的免疫系统抑制剂
|
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
US20180147257A1
(en)
|
2015-05-22 |
2018-05-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Btn3a ectodomain proteins and methods of use
|
|
SG10201913573UA
(en)
*
|
2015-10-01 |
2020-03-30 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
|
CN108473958A
(zh)
|
2015-10-30 |
2018-08-31 |
癌症研究技术有限公司 |
非造血组织驻留γδT细胞的扩增及这些细胞的用途
|
|
KR102803158B1
(ko)
|
2015-12-02 |
2025-05-08 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
|
|
GB201521389D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
CN109071632B
(zh)
*
|
2016-02-05 |
2022-12-30 |
奥里尼斯生物科学私人有限公司 |
靶向性治疗剂及其用途
|
|
EP3436475A1
(en)
|
2016-03-29 |
2019-02-06 |
STCube & Co., Inc. |
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
|
|
WO2018082590A1
(zh)
*
|
2016-11-02 |
2018-05-11 |
北京蛋白质组研究中心 |
肿瘤免疫治疗靶标及其应用
|
|
WO2018201130A1
(en)
|
2017-04-28 |
2018-11-01 |
The Brigham And Women's Hospital, Inc. |
Targeting gamma-delta t cells in obesity and cachexia
|
|
CN111148762A
(zh)
|
2017-05-31 |
2020-05-12 |
斯特库伯株式会社 |
免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
|
|
CN111051346A
(zh)
|
2017-05-31 |
2020-04-21 |
斯特库伯株式会社 |
使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
|
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
EP4467146A3
(en)
|
2017-09-15 |
2025-05-07 |
King's College London |
Compositions and methods for enhancing gamma delta t cells in the gut
|
|
KR102764182B1
(ko)
|
2017-09-21 |
2025-02-07 |
임체크 테라퓨틱스 |
Btn2에 대해 특이성을 갖는 항체 및 이의 용도
|
|
BR112021013193A2
(pt)
*
|
2019-01-07 |
2021-09-28 |
Shattuck Labs, Inc. |
Proteínas heterodiméricas para modulação de células t gama delta
|